Information Provided By:
Fly News Breaks for January 28, 2020
Jan 28, 2020 | 10:19 EDT
Mizuho analyst Mara Goldstein noted that Incyte announced positive topline results from its TRuE-AD2 study evaluating ruxolitinib cream in patients with atopic dermatitis, or eczema. While the efficacy and safety data was consistent to what was observed in the Phase 2 trial, this was largely anticipated, according to Goldstein. She sees ruxolitinib cream as a positive, but believes the bigger questions for Incyte relate to commercialization in atopic dermatitis and the data for the TRuE-V program in vitiligo, which she sees as the larger opportunity. She keeps a Neutral rating on Incyte shares.